Repository logo
 
Publication

Enhanced 3T3-L1 differentiation into adipocytes by pioglitazone pharmacological activation of peroxisome proliferator activated receptor-gamma (PPAR-gamma)

dc.contributor.authorTeixeira, Catarina
dc.contributor.authorSousa, André P.
dc.contributor.authorSantos, Inês
dc.contributor.authorRocha, Ana Catarina
dc.contributor.authorAlencastre, Inês
dc.contributor.authorPereira, Ana Cláudia
dc.contributor.authorMartins-Mendes, Daniela
dc.contributor.authorBarata, Pedro
dc.contributor.authorBaylina, Pilar
dc.contributor.authorFernandes, Rúben
dc.date.accessioned2022-11-23T17:21:38Z
dc.date.available2022-11-23T17:21:38Z
dc.date.issued2022-05-24
dc.description.abstractDespite the primary function of pioglitazone in antidiabetic treatment, this drug is a potent inducer of PPAR-γ, a crucial receptor that is involved in adipocyte differentiation. In this work, we propose an optimized methodology to enhance the differentiation of 3T3-L1 fibroblasts into adipocytes. This process is crucial for adipocyte secretome release, which is fundamental for understanding the molecular mechanisms that are involved in obesity for in vitro studies. To achieve this, a pioglitazone dose-response assay was determined over a range varying from 0 to 10 µM. Lipid accumulation was evaluated using Oil-Red-O. The results showed that 10 µM pioglitazone enhanced differentiation and increased secretome production. This secretome was then added into two cell lines: PC3 and RAW264.7. In the PC3 cells, an increase of aggressiveness was observed in terms of viability and proliferation, with the increase of anti-inflammatory cytokines. Conversely, in RAW264.7 cells, a reduction of viability and proliferation was observed, with a decrease in the overexpression of pro-inflammatory cytokines. Overall, the present work constitutes an improved method for adipocyte secretome production that is suitable for experimental biology studies and that could help with our understanding of the molecular mechanisms underlying adiposity influence in other cells.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationTeixeira, C., Sousa, A. P., Santos, I., Rocha, A. C., Alencastre, I., Pereira, A. C., Martins-Mendes, D., Barata, P., Baylina, P., & Fernandes, R. (2022). Enhanced 3T3-L1 Differentiation into Adipocytes by Pioglitazone Pharmacological Activation of Peroxisome Proliferator Activated Receptor-Gamma (PPAR-γ). Biology, 11(6), 806. https://doi.org/10.3390/biology11060806pt_PT
dc.identifier.doi10.3390/biology11060806pt_PT
dc.identifier.eissn2079-7737
dc.identifier.urihttp://hdl.handle.net/10400.22/21053
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMDPIpt_PT
dc.relation.publisherversionhttps://www.mdpi.com/2079-7737/11/6/806/htmpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subject3T3-L1pt_PT
dc.subjectPioglitazonept_PT
dc.subjectPPAR-γpt_PT
dc.subjectAdipocyte differentiationpt_PT
dc.titleEnhanced 3T3-L1 differentiation into adipocytes by pioglitazone pharmacological activation of peroxisome proliferator activated receptor-gamma (PPAR-gamma)pt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage13pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleBiologypt_PT
oaire.citation.volume11pt_PT
person.familyNameBAYLINA MACHADO
person.givenNamePILAR
person.identifier.ciencia-id1419-F23D-4920
person.identifier.orcid0000-0002-3740-862X
person.identifier.ridB-5134-2010
person.identifier.scopus-author-id56534079700
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationb1482a24-d9d8-419d-af68-6df1a75afb3f
relation.isAuthorOfPublication.latestForDiscoveryb1482a24-d9d8-419d-af68-6df1a75afb3f

Files

Original bundle
Now showing 1 - 2 of 2
No Thumbnail Available
Name:
ART_Pilar Baylina.pdf
Size:
3.81 MB
Format:
Adobe Portable Document Format
No Thumbnail Available
Name:
Licença (2).txt
Size:
1.74 KB
Format:
Plain Text
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: